Guardant Health (NASDAQ:GH) Posts Quarterly Earnings Results, Beats Estimates By $0.46 EPS

Guardant Health (NASDAQ:GH) released its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.46, FiscalAI reports. The firm had revenue of $360.98 million for the quarter, compared to the consensus estimate of $350.72 million. The firm’s revenue was up 36.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.74) earnings per share.

Here are the key takeaways from Guardant Health’s conference call:

• Revenue growth accelerated, and Guardant raised its 2026 outlook. Third-quarter revenue increased 36% to $361 million, prompting the company to raise full-year revenue guidance to $1.36 billion–$1.37 billion, or approximately 38%–40% growth.
• Shield screening showed strong adoption and expanding coverage. Shield volume rose 246% to 83,000 tests, while new payer decisions are expected to bring coverage to about 100 million people by 2027; management raised its full-year Shield volume and revenue outlook.
• Oncology growth was supported by rising test volumes and product milestones. Oncology volume increased 58%, with Reveal volumes more than doubling; Guardant also received FDA approval for ESR1 monitoring, submitted Guardant360 Tissue for FDA review, and expects to launch Reveal Ultra clinically before year-end.
• Cost improvements and lower cash burn supported the path toward profitability. Non-GAAP gross margin improved to 67%, Shield cost per test fell to $330—below the company’s year-end target—and adjusted EBITDA loss narrowed to $37 million; Guardant reiterated its goal of company-wide cash-flow breakeven by the end of 2027.
• Full-year free-cash-flow-burn guidance increased. Guardant now expects $205 million–$220 million of burn, partly because $10 million–$15 million in Guardant360 Liquid CDx payments are expected to shift into 2027 due to a CMS billing-system delay; the company also plans continued investment in commercial expansion.

Guardant Health Stock Down 1.7%

NASDAQ:GH opened at $150.87 on Friday. The firm has a market cap of $20.25 billion, a price-to-earnings ratio of -41.00 and a beta of 1.67. Guardant Health has a 12 month low of $74.55 and a 12 month high of $191.05. The company’s 50 day moving average is $169.31 and its 200-day moving average is $132.00.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Roth Capital assumed coverage on Guardant Health in a research report on Thursday, October 22nd. They issued a “buy” rating and a $200.00 target price on the stock. Rothschild & Co Redburn initiated coverage on Guardant Health in a research note on Tuesday, September 8th. They issued a “buy” rating and a $203.00 price target on the stock. Mizuho lifted their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Stephens upped their target price on shares of Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Finally, Sanford C. Bernstein restated an “outperform” rating and set a $210.00 target price on shares of Guardant Health in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $191.00.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Third-quarter revenue increased 36% year over year to $361 million, above the cited analyst estimate of about $351 million. Oncology revenue rose 25%, while oncology test volumes climbed 58% to 117,000. Guardant also raised its 2026 revenue guidance. Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The reported quarterly loss was $0.29 per share, narrower than the $0.39 loss a year earlier. Guardant Health Reports Q3 Loss, Tops Revenue Estimates
• Neutral Sentiment: A separate article suggested GH could be undervalued, while noting a board appointment as a factor investors may consider in assessing the company’s valuation. Guardant Health Could Be 17% Undervalued As Board Appointment Tests Valuation
• Negative Sentiment: The main drag was a higher cash-burn forecast, which raised concerns about spending and the path to profitability despite accelerating sales. Reports said the stock declined following the earnings announcement. Guardant Health Shares Fall as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth

Insider Activity

In related news, Director Steve E. Krognes sold 6,674 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $175.74, for a total value of $1,172,888.76. Following the completion of the sale, the director directly owned 7,906 shares in the company, valued at $1,389,400.44. This represents a 45.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Terilyn J. Monroe sold 46,300 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total value of $7,645,056.00. Following the transaction, the insider owned 22,979 shares of the company’s stock, valued at $3,794,292.48. The trade was a 66.83% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 163,060 shares of company stock valued at $27,538,217. Insiders own 5.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.